Philip Astley-Sparke is Chief Executive Officer and co-founder of Replimune and has served as a member of our Board since our formation in 2015. Previously he was the President and CEO of BioVex Inc, which developed the first oncolytic therapy which was approved in the U.S. and Europe in 2015. Philip relocated the Company from the UK to the US in 2005 before Biovex was acquired by Amgen for up to $1bn in 2011. Subsequent to BioVex/Amgen, Philip was President at uniQure where he established their US infrastructure including the world’s largest gene therapy manufacturing facility and served as the Company’s Chairman from 2016 until June 2021. Philip also previously served as Chairman of the board of directors of Oxyrane Limited, a biotechnology company, from 2012 to 2020. Philip is currently a Venture Partner at Forbion Capital and serves on the board of Forbion European Acquisition Corp. Philip received a BSc in Cellular and Molecular Pathology from Bristol University UK, qualified as a Chartered Accountant with Arthur Andersen and was a healthcare investment banker with Robert Fleming / Chase H&Q.